Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company cut its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 47,915 shares of the company’s stock after selling 5,630 shares during the period. The Manufacturers Life Insurance Company’s holdings in Intellia Therapeutics were worth $559,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. ARK Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock worth $146,174,000 after buying an additional 280,946 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Intellia Therapeutics by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock worth $118,816,000 after buying an additional 562,249 shares during the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth $43,177,000. Geode Capital Management LLC increased its holdings in shares of Intellia Therapeutics by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company’s stock worth $27,865,000 after buying an additional 45,930 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Intellia Therapeutics by 36.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company’s stock worth $23,042,000 after buying an additional 528,962 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Morgan Stanley downgraded Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $56.00 to $11.00 in a report on Monday, January 27th. Wolfe Research upgraded Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 price objective for the company in a report on Monday, April 21st. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Monday, March 3rd. Chardan Capital reiterated a “buy” rating and issued a $68.00 price target on shares of Intellia Therapeutics in a report on Friday, May 9th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $36.90.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $8.50 on Friday. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $28.18. The company’s 50-day simple moving average is $8.00 and its 200-day simple moving average is $10.82. The stock has a market capitalization of $880.46 million, a price-to-earnings ratio of -1.56 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. Intellia Therapeutics’s revenue was down 42.6% compared to the same quarter last year. During the same quarter last year, the company earned ($1.12) EPS. As a group, research analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.